Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA NASDAQ:CMPX NASDAQ:ORIC NASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$10.07$8.08$3.92▼$19.15$90.73M0.193,235 shs144,862 shsCMPXCompass Therapeutics$2.02$2.83$1.61▼$6.88$363.78M0.893.79 million shs9.27 million shsORICOric Pharmaceuticals$8.49$8.98$7.23▼$14.93$878.86M1.041.77 million shs2.77 million shsPBYIPuma Biotechnology$7.56$7.26$3.03▼$7.90$384.80M1.21192,563 shs427,438 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics0.00%-3.27%+7.82%+105.09%+25.56%CMPXCompass Therapeutics0.00%-0.49%+5.21%-60.78%-15.13%ORICOric Pharmaceuticals0.00%+2.66%+0.35%-23.92%-7.92%PBYIPuma Biotechnology0.00%+3.14%+7.23%+23.53%+122.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$10.07$8.08$3.92▼$19.15$90.73M0.193,235 shs144,862 shsCMPXCompass Therapeutics$2.02$2.83$1.61▼$6.88$363.78M0.893.79 million shs9.27 million shsORICOric Pharmaceuticals$8.49$8.98$7.23▼$14.93$878.86M1.041.77 million shs2.77 million shsPBYIPuma Biotechnology$7.56$7.26$3.03▼$7.90$384.80M1.21192,563 shs427,438 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics0.00%-3.27%+7.82%+105.09%+25.56%CMPXCompass Therapeutics0.00%-0.49%+5.21%-60.78%-15.13%ORICOric Pharmaceuticals0.00%+2.66%+0.35%-23.92%-7.92%PBYIPuma Biotechnology0.00%+3.14%+7.23%+23.53%+122.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.00Hold$9.50-5.66% DownsideCMPXCompass Therapeutics 2.86Moderate Buy$12.91539.06% UpsideORICOric Pharmaceuticals 2.76Moderate Buy$18.92122.81% UpsidePBYIPuma Biotechnology 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest ATRA, ORIC, PBYI, and CMPX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026ORICOric Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/11/2026ATRAAtara Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (E+)6/8/2026ORICOric Pharmaceuticals BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/8/2026ORICOric Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/4/2026CMPXCompass Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/1/2026CMPXCompass Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$6.005/22/2026ORICOric Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/18/2026ATRAAtara Biotherapeutics Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/15/2026ORICOric Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$15.005/11/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/8/2026ATRAAtara Biotherapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold ➝ Buy$6.00 ➝ $13.00(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$120.77M0.75$4.86 per share2.07($5.34) per share-1.89CMPXCompass Therapeutics$850K427.98N/AN/A$1.11 per share1.82ORICOric PharmaceuticalsN/AN/AN/AN/A$3.90 per shareN/APBYIPuma Biotechnology$228.40M1.68$0.83 per share9.06$2.59 per share2.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics$32.69M-$0.67N/A50.35N/A-40.91%-79.12%-35.29%8/10/2026 (Estimated)CMPXCompass Therapeutics-$66.49M-$0.41N/AN/AN/AN/A-39.75%-35.29%8/10/2026 (Estimated)ORICOric Pharmaceuticals-$129.47M-$1.44N/AN/AN/AN/A-35.33%-33.31%8/11/2026 (Estimated)PBYIPuma Biotechnology$31.11M$0.4815.7568.73N/A10.69%20.30%12.05%8/6/2026 (Estimated)Latest ATRA, ORIC, PBYI, and CMPX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ATRAAtara Biotherapeutics-$0.3295-$0.29+$0.0395-$0.29$2.90 million$0.52 million5/7/2026Q1 2026PBYIPuma Biotechnology-$0.13-$0.04+$0.09-$0.07$42.00 million$44.81 million5/5/2026Q1 2026CMPXCompass Therapeutics-$0.10-$0.10N/A-$0.10($0.82) millionN/A5/4/2026Q1 2026ORICOric Pharmaceuticals-$0.31-$0.34-$0.03-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A2.162.16CMPXCompass TherapeuticsN/A19.0419.04ORICOric PharmaceuticalsN/A16.3316.33PBYIPuma BiotechnologyN/A2.382.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%CMPXCompass Therapeutics68.43%ORICOric Pharmaceuticals95.05%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics41.20%CMPXCompass Therapeutics18.70%ORICOric Pharmaceuticals5.70%PBYIPuma Biotechnology22.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3309.01 million5.30 millionNo DataCMPXCompass Therapeutics20180.09 million146.41 millionNot OptionableORICOric Pharmaceuticals80103.52 million97.62 millionOptionablePBYIPuma Biotechnology20050.90 million39.60 millionOptionableATRA, ORIC, PBYI, and CMPX HeadlinesRecent News About These CompaniesPuma Biotechnology Shareholders Back Governance, Reject Warrant ExtensionJune 16, 2026 | tipranks.comPuma Biotechnology (NASDAQ:PBYI) Director Brian Stuglik Sells 8,100 SharesJune 16, 2026 | insidertrades.comPuma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving Average - Here's WhyJune 12, 2026 | americanbankingnews.comPuma Biotechnology Stock Rises 19% in 3 Months: Here's WhyJune 11, 2026 | zacks.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 3, 2026 | businesswire.comPuma Biotechnology Reveal Hidden Strength Amid Rising Market FocusMay 17, 2026 | kalkinemedia.comKPuma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft EarningsMay 14, 2026 | finance.yahoo.comEarnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00May 11, 2026 | finance.yahoo.comPBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance RaisedMay 8, 2026 | zacks.comPuma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comPuma Biotech: Q1 Earnings SnapshotMay 8, 2026 | sfgate.comPuma Biotech (PBYI) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2026 | zacks.comPuma Biotechnology Reports First Quarter 2026 Financial ResultsMay 7, 2026 | businesswire.comPuma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial ResultsApril 23, 2026 | finance.yahoo.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 | businesswire.comPuma Biotechnology Stock Declines More Than 9% in a Month: Here's WhyMarch 18, 2026 | zacks.comIRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?March 12, 2026 | zacks.comPBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 ViewFebruary 27, 2026 | zacks.comPuma Biotechnology Inc (PBYI) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...February 27, 2026 | finance.yahoo.comPuma anticipates $194M–$198M NERLYNX revenue for 2026 while advancing alisertib clinical programsFebruary 26, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Mission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026From Runway to Riches: Victoria's Secret's New LookBy Jeffrey Neal Johnson | June 4, 2026MarketBeat Week in Review – 06/08 - 06/12By MarketBeat Staff | June 13, 2026Survey Reveals the Historic Main Streets People Most Want Revived [2026]By MarketBeat Staff | June 2, 2026ATRA, ORIC, PBYI, and CMPX Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$10.07 0.00 (0.00%) As of 06/18/2026 04:00 PM EasternAtara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Compass Therapeutics NASDAQ:CMPX$2.02 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$2.04 +0.02 (+1.24%) As of 06/18/2026 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Oric Pharmaceuticals NASDAQ:ORIC$8.49 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$8.71 +0.22 (+2.59%) As of 06/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Puma Biotechnology NASDAQ:PBYI$7.56 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$7.58 +0.02 (+0.20%) As of 06/18/2026 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
